Alpha 2.0
Login Register
» Authors » R E Coleman

R E Coleman

Explore the profile of R E Coleman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 591
Citations 10630
Followers 0
Related Specialties
Oncology
Nuclear Medicine
Radiology
Top 10 Co-Authors
R J Jaszczak
K L Greer
F R COBB
M W Hanson
J M Hoffman
T G Turkington
R D Rubens
B W Hancock
R H Jones
M J Welch
Published In
J Nucl Med
Br J Cancer
Radiology
Phys Med Biol
Am J Cardiol
Affiliations
Soon will be listed here.
Recent Articles
1.
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
Coleman R, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, et al.
J Bone Oncol . 2018 Dec; 13:123-135. PMID: 30591866
Patients And Methods: 3360 patients with stage II/III breast cancer were included in an academic, international, phase III, randomized, open label trial. Patients were followed up on a regular schedule...
2.
The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer
Anderson R, Mansi J, Coleman R, Adamson D, Leonard R
Eur J Cancer . 2017 Nov; 87:58-64. PMID: 29117576
Aim: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment....
3.
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial
Leonard R, Adamson D, Bertelli G, Mansi J, Yellowlees A, Dunlop J, et al.
Ann Oncol . 2017 May; 28(8):1811-1816. PMID: 28472240
Background: Chemotherapy-induced premature ovarian insufficiency (POI) impacts fertility and other aspects of women's health. The OPTION trial tested whether administration of a gonadotropin-releasing hormone agonist during chemotherapy for early breast...
4.
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, OSullivan J, et al.
Ann Oncol . 2017 Apr; 28(5):1090-1097. PMID: 28453701
Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223,...
5.
Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia
Winter M, Tidy J, Hills A, Ireson J, Gillett S, Singh K, et al.
Gynecol Oncol . 2016 Oct; 143(3):565-570. PMID: 27756557
Objective: To evaluate the outcome of patients treated with second-line chemotherapy for methotrexate-resistant low-risk GTN at the Sheffield Centre, UK between 2001 and 2015, including the novel use of single-agent...
6.
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
Nilsson S, Cislo P, Sartor O, Vogelzang N, Coleman R, OSullivan J, et al.
Ann Oncol . 2016 Feb; 27(5):868-74. PMID: 26912557
Background: Radium-223 dichloride (radium-223), a first-in-class α-emitting radiopharmaceutical, is recommended in both pre- and post-docetaxel settings in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases based on overall...
7.
Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
Lester J, Dodwell D, Brown J, Purohit O, Gutcher S, Ellis S, et al.
J Bone Oncol . 2016 Feb; 1(2):57-62. PMID: 26909256
Purpose: The ARIBON trial is a double blind, randomised, placebo controlled study designed to evaluate the impact of ibandronate on bone mineral density (BMD) in women taking anastrozole for adjuvant...
8.
A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts
Brown H, Ottewell P, Evans C, Coleman R, Holen I
J Bone Oncol . 2016 Feb; 1(2):47-56. PMID: 26909255
We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast...
9.
Late spontaneous resolution of persistent molar pregnancy
Taylor F, Short D, Harvey R, Winter M, Tidy J, Hancock B, et al.
BJOG . 2016 Jan; 123(7):1175-81. PMID: 26774079
Objective: To determine the outcome of women with persistently raised but falling human chorionic gonadotrophin (hCG) levels 6 months after surgical evacuation of a molar pregnancy. Design: An 11-year retrospective...
10.
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
Kroep J, Charehbili A, Coleman R, Aft R, Hasegawa Y, Winter M, et al.
Eur J Cancer . 2016 Jan; 54:57-63. PMID: 26722766
Purpose: The addition of bisphosphonates to adjuvant therapy improves survival in postmenopausal breast cancer (BC) patients. We report a meta-analysis of four randomised trials of neoadjuvant chemotherapy (CT) +/- zoledronic...